Quick Take
Simulations Plus (SLP) has announced the acquisition of Lixoft for up to $16.5 million.
Lixoft has developed drug development simulation modeling software.
With the deal, SLP gains additional modeling capabilities and a stronger European geographic presence.
SLP has performed well as a stock in the volatile markets, but I view it as priced for perfection and my opinion is Neutral at its current level.
Target Company
Paris, France-based Lixoft was founded to develop a suite of software tools that enable biopharma research firms and others to perform PKPD (PharmacoKinetic / PharmacoDynamic)